Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Declines By 17.5%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling 2,305 shares, a drop of 17.5% from the February 26th total of 2,795 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average daily volume of 11,098 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Trading of Global X Genomics & Biotechnology ETF

Large investors have recently added to or reduced their stakes in the business. Flow Traders U.S. LLC raised its stake in Global X Genomics & Biotechnology ETF by 52.4% during the 2nd quarter. Flow Traders U.S. LLC now owns 238,725 shares of the company’s stock valued at $2,012,000 after acquiring an additional 82,063 shares in the last quarter. U.S. Capital Wealth Advisors LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF during the fourth quarter valued at $575,000. Sei Investments Co. raised its stake in shares of Global X Genomics & Biotechnology ETF by 110.4% during the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after purchasing an additional 12,105 shares in the last quarter. Jane Street Group LLC lifted its holdings in Global X Genomics & Biotechnology ETF by 7.7% in the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after purchasing an additional 10,308 shares during the period. Finally, Smartleaf Asset Management LLC lifted its holdings in Global X Genomics & Biotechnology ETF by 30.9% in the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after purchasing an additional 4,615 shares during the period. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Stock Up 1.3%

NASDAQ GNOM traded up $0.57 on Wednesday, hitting $44.31. The stock had a trading volume of 12,385 shares, compared to its average volume of 9,868. Global X Genomics & Biotechnology ETF has a one year low of $27.20 and a one year high of $51.42. The stock has a market cap of $49.63 million, a price-to-earnings ratio of -18.94 and a beta of 1.22. The company’s 50-day moving average is $45.91 and its two-hundred day moving average is $44.67.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.